Primary analysis of ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) Meeting Abstract
| Authors: | Chaganti, S.; Cwynarski, K.; Cunningham, D.; Locke, F. L.; Miklos, D. B.; Jacobson, C. A.; Perales, M. A.; Kersten, M. J.; Oluwole, O. O.; Ghobadi, A.; Rapoport, A. P.; McGuirk, J. P.; Pagel, J. M.; Muñoz , J.; Farooq, U.; van Meerten, T.; Reagan, P. M.; Sureda, A.; Flinn, I. W.; Vandenberghe, P.; Song, K. W.; Dickinson, M.; Minnema, M. C.; Riedell, P. A.; Leslie, L. A.; Yang, Y.; Filosto, S.; Schupp, M.; To, C.; Cheng, P.; Gordon, L. I.; Radford, J.; Westin, J. R. |
| Abstract Title: | Primary analysis of ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) |
| Meeting Title: | 62nd Annual Scientific Meeting of the British Society for Haematology |
| Journal Title: | British Journal of Haematology |
| Volume: | 197 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Apr 3-5 |
| Meeting Location: | Manchester, United Kingdom |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2022-04-01 |
| Start Page: | 20 |
| End Page: | 22 |
| Language: | English |
| ACCESSION: | WOS:000776484300021 |
| PROVIDER: | wos |
| PUBMED: | 35362090 |
| DOI: | 10.1111/bjh.18132 |
| Notes: | Meeting Abstract: BSH22-OR14 -- Hybrid meeting, also held virtually -- Source: Wos |
